Current US Food and Drug Administration (FDA)–approved indications for the use of octreotide in adults include acromegaly, severe diarrhea and/or flushing secondary to carcinoid tumors, and severe diarrhea secondary to VIP‐secreting tumors. Here, VIP is linked to carcinoid tumor.